CIBC Asset Management
ABUS icon

CIBC Asset Management’s Arbutus Biopharma ABUS Stock Holding History

CIBC Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,382
Closed -$64.7K – 1429
2026
Q1 		$64.7K Hold
14,382
– – ﹤0.01% 1336
2025
Q4 		$69.2K Buy
+14,382
New +$64.7K ﹤0.01% 1325

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CIBC Asset Management's ABUS Position: Q2 2026 in Review

CIBC Asset Management sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 14,382 shares — an estimated $64.7K sold.

CIBC Asset Management first reported a position in ABUS in Q4 2025 and held it in 2 quarters. The position peaked at $69.2K in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • CIBC Asset Management reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • CIBC Asset Management sold 14,382 Arbutus Biopharma shares in Q2 2026, an estimated $64.7K.
  • CIBC Asset Management first reported a position in Arbutus Biopharma in Q4 2025 and held it in 2 quarters.
  • CIBC Asset Management's Arbutus Biopharma position peaked at $69.2K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.